Table 5.
Relation between treatment and outcomes of patients with prostate cancer (n = 50).
| Treatment | Relapse | Mortality | ||||||
|---|---|---|---|---|---|---|---|---|
| Patients with prostate cancer (n = 39), n (%) | Absent (n = 23), n (%) |
Present (n = 16), n (%) |
p* | Patients with prostate cancer (n = 50), n (%) | Alive (n = 35), n (%) | Died (n = 15), n (%) | p* | |
| Local radiotherapy | ||||||||
| No | 1 (2.6) | 0 (0) | 1 (100) | 0.410 | 12 (24) | 2 (16.7) | 10 (83.3) | <0.001† |
| Yes | 38 (97.4) | 23 (60.5) | 15 (39.5) | 38 (76) | 33 (86.8) | 5 (13.2) | ||
| Hormonal deprivation | ||||||||
| LHRH | 15 (38.5) | 12 (80) | 3 (20) | 0.035† | 15 (30) | 12 (80) | 3 (20) | 0.502 |
| LHRH + AR blockers | 24 (61.5) | 11 (45.8) | 13 (54.2) | 35 (70) | 23 (65.7) | 12 (34.3) | ||
| Neoadjuvant hormonal | ||||||||
| No | 38 (97.4) | 23 (60.5) | 15 (39.5) | 0.410 | 38 (76) | 33 (86.8) | 5 (13.2) | <0.001† |
| Yes | 1 (2.6) | 0 (0) | 1 (100) | 12 (24) | 2 (16.7) | 10 (83.3) | ||
| Concurrent hormonal | ||||||||
| No | 7 (17.9) | 6 (85.7) | 1 (14.3) | 0.206 | 18 (36) | 8 (44.4) | 10 (55.6) | 0.003† |
| Yes | 32 (82.1) | 17 (53.1) | 15 (46.9) | 32 (64) | 27 (84.4) | 5 (15.6) | ||
| Posttreatment prostate-specific antigen, ng/mL | ||||||||
| ≤0.5 | 28 (71.8) | 18 (64.3) | 10 (35.7) | 0.307 | 34 (68) | 24 (70.6) | 10 (29.4) | 1.000 |
| >0.5 | 11 (28.2) | 5 (45.5) | 6 (54.5) | 16 (32) | 11 (68.8) | 5 (31.2) | ||
| Relapse | (n = 39) | (n = 33) | (n = 6) | |||||
| Absent | 23 (59) | 21 (91.3) | 2 (8.7) | 0.205 | ||||
| Present | 16 (41) | 12 (75) | 4 (25) | |||||
AR = androgen receptor; LHRH = luteinizing hormone-releasing hormone.
Categorical variables are expressed as number (percentage).
*χ2 Test.
†p < 0.05 (significant).